2006
DOI: 10.1161/circulationaha.105.598987
|View full text |Cite
|
Sign up to set email alerts
|

Vascular Biomarkers and Surrogates in Cardiovascular Disease

Abstract: Abstract-Cardiovascular biomarker research efforts have resulted in the identification of new risk factors and novel drug targets, as well as the establishment of treatment guidelines. Government agencies, academic research institutions, diagnostic industries, and pharmaceutical companies all recognize the importance of biomarkers in advancing therapies to improve public health. In drug development, biomarkers are used to evaluate early signals of efficacy and safety, to select dose, and to identify the target… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

1
70
0
2

Year Published

2006
2006
2020
2020

Publication Types

Select...
7
2
1

Relationship

0
10

Authors

Journals

citations
Cited by 143 publications
(74 citation statements)
references
References 53 publications
1
70
0
2
Order By: Relevance
“…This method is well-established for assessment of endothelial function of conduit arteries 27,28 and has been used in previous own trials. 29,30 This noninvasive standard method is based on the application of a standardized hyperemic stimulus that induces a rapid dilation response of the brachial artery.…”
Section: Assessment Of Fmd Of the Brachial Arterymentioning
confidence: 99%
“…This method is well-established for assessment of endothelial function of conduit arteries 27,28 and has been used in previous own trials. 29,30 This noninvasive standard method is based on the application of a standardized hyperemic stimulus that induces a rapid dilation response of the brachial artery.…”
Section: Assessment Of Fmd Of the Brachial Arterymentioning
confidence: 99%
“…Carotid intima media thickness (IMT) is an intermediate phenotype of atherosclerosis and one of the strongest predictors of cardiovascular events, including myocardial infarction and stroke (12). Reduction in IMT over time entails a parallel decrease in the risk for cardiovascular events, and this parameter is considered as a valid surrogate end point by the Food and Drug Administration (13) and the European Medicines Agency (14). The validity of IMT as a cardiovascular risk biomarker in the CKD population is supported by studies in patients with predialysis CKD (15) and patients on dialysis (6,16).…”
Section: Introductionmentioning
confidence: 99%
“…Previous studies proved that CIMT is an early marker of atherosclerosis [22]. Measurement of CIMT is widely used and predicts cardiovascular events in subjects without clinically evident disease [23]. Hence, CIMT thickening is found when the vessels develop atherosclerosis and becomes stiffer.…”
Section: Discussionmentioning
confidence: 99%